Interleukin (IL)-4 Antibody Global Market Report 2025
상품코드:1889491
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
인터루킨(IL)-4 항체 시장 규모는 최근 수년간 현저한 성장을 보이고 있습니다. 2024년 21억 3,000만 달러에서 2025년에는 23억 2,000만 달러로, CAGR 9.0%로 확대되었습니다. 지난 수년간의 성장은 알레르기성 질환과 염증성 질환의 유병률 증가, 단일클론항체 요법의 도입 확대, 면역요법 치료에 대한 인지도 향상, 의료 지출 증가, 맞춤 의료에 대한 주목 증가에 의해 발생하였습니다.
인터루킨(IL)-4 항체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 32억 3,000만 달러에 달하고, CAGR은 8.6%를 나타낼 전망입니다. 예측기간의 성장요인으로는 만성호흡기 질환의 발생률 상승, 표적 생물학적 요법에 대한 수요 증가, 자가면역질환의 임상검사 확대, 바이오시밀러 개발에 대한 투자 증가, 제약기업과 생명공학기업 간의 연계 강화 등이 있습니다. 예측기간의 주요 동향으로는 항체공학기술의 진보, 사이토카인 조절에 관한 연구개발, 재조합 항체생산의 혁신, 차세대 생물제제의 개발, 인공지능(AI) 기반 신약 개발 플랫폼의 통합 등이 있습니다.
알레르기 질환의 유병률 증가는 향후 인터루킨(IL)-4 항체 시장의 성장을 이끌 것으로 예측됩니다. 알레르기 질환은 꽃가루, 먼지, 음식 등 무해한 물질에 대해 신체가 과도하게 반응하는 면역계 장애이며, 염증, 가려움, 호흡 곤란 등의 증상을 일으킵니다. 알레르기 질환의 유병률 상승은 도시화와 환경 변화에 의한 오염물질 및 알레르겐에 대한 노출 증가가 면역과잉반응을 일으키기 때문입니다. 인터루킨(IL)-4 항체는 IL-4 채널을 특이적으로 표적으로 함으로써 알레르기 질환의 관리를 지원하고 면역계의 과잉반응을 억제하는 효과가 있습니다. 염증, 가려움, 호흡 곤란 등의 증상 완화에 기여하여 환자의 편안함과 삶의 질을 향상시킵니다. 예를 들어 호주 비영리 단체인 국립 천식 평의회(NAC)에 따르면 2025년 2월 호주에서 천식 관련 사망은 총 474건을 기록했습니다. 이는 2022년 473건에서 0.2% 미세 증가를 보였으며, 사망자 중 여성은 68.6%, 남성은 31.4%를 차지했습니다. 따라서 알레르기 질환의 유병률 증가는 인터루킨(IL)-4 항체 시장의 성장을 이끌고 있습니다.
인터루킨(IL)-4 항체 시장에서 사업을 전개하는 주요 기업은 종양 내성 문제에 대처하고 항암 효과를 높이기 위해 차세대 이중특이적 항체 등의 혁신적 제품 개발에 주력하고 있습니다. 차세대 이중특이적 항체는 두 개의 서로 다른 항원 또는 에피토프에 동시에 결합하도록 설계된 재조합 항체를 말하며, 종래의 단일 표적 항체와 비교하여 여러 채널을 동시에 조절함으로써 치료 효과를 높이고, 특이성을 향상시키며, 부작용을 완화할 가능성을 가지고 있습니다. 예를 들어, 2025년 2월에는 중국에 본사를 둔 바이오의약품 기업인 아케소사가 이중특이적 항체 'AK139'에 대해 중국 국가약품감독관리국(NMPA)으로부터 임상시험계획 승인 신청(IND)에 대해 승인을 받았습니다. AK139는 인터루킨-4 수용체 α와 ST2 수용체의 이중 표적화를 통합하여 인터루킨-4, 인터루킨-13, 인터루킨-33 채널을 동시에 차단합니다. 이는 단일 표적 항체를 넘어서는 기전 상의 상승효과를 제공합니다. 이 접근법은 염증성 사이토카인의 방출과 조직 침윤을 보다 효과적으로 억제하는 것을 목표로 하며, 호흡기 질환 및 피부 질환과 관련된 염증에 대해 보다 강력하고 지속적인 제어를 제공할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 인터루킨(IL)-4 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 인터루킨(IL)-4 항체 시장 : 성장률 분석
세계의 인터루킨(IL)-4 항체 시장 실적 : 규모와 성장(2019-2024년)
세계의 인터루킨(IL)-4 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 인터루킨(IL)-4 항체 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 인터루킨(IL)-4 항체 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
다중클론항체
세계의 인터루킨(IL)-4 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
효소 면역 측정법
면역조직화학(동결절편)
면역조직화학 파라핀
웨스턴 블롯
기타
세계의 인터루킨(IL)-4 항체 시장 : 최종사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제약기업
생명공학 기업
학술연구기관
수탁연구기관(CRO)
세계의 인터루킨(IL)-4 항체 시장 : 단일클론항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
인간화 단일클론항체
키메라 단일클론항체
완전 인간화 단일클론항체
마우스 단일클론항체
세계의 인터루킨(IL)-4 항체 시장 : 다중클론항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
토끼 다중클론항체
염소 다중클론항체
양 다중클론항체
마우스 다중클론항체
당나귀 다중클론항체
제7장 지역별 및 국가별 분석
세계의 인터루킨(IL)-4 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 인터루킨(IL)-4 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
인터루킨(IL)-4 항체 시장 : 경쟁 구도
인터루킨(IL)-4 항체 시장 : 기업 프로파일
Sanofi SA
Thermo Fisher Scientific Inc.
Merck KGaA
Becton Dickinson and Company
Regeneron Pharmaceuticals Inc.
제31장 기타 주요 기업 및 혁신 기업
Bio-Rad Laboratories Inc.
GeneTex Inc.
Miltenyi BIoTec BV & Co. KG
GenScript BIoTech Corporation
Cell Signaling Technology Inc.
Elabscience BIoTechnology Inc.
RayBIoTech Life Inc.
Santa Cruz BIoTechnology Inc.
Atlas Antibodies AB
Creative Biolabs Inc.
Abnova(대만) Corporation
Wuhan Fine BIoTech Co. Ltd.
United States Biological LLC
NSJ Bioreagents
Boster Biological Technology Co. Ltd.
제32장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 전략
인터루킨(IL)-4 항체 시장(2029년) : 새로운 기회를 제공하는 국가
인터루킨(IL)-4 항체 시장(2029년) : 새로운 기회를 제공하는 부문
인터루킨(IL)-4 항체 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Interleukin (IL) 4 antibody is a laboratory-produced antibody that specifically targets IL 4, a cytokine that regulates the immune system, particularly by promoting Th2 cell differentiation and antibody production. It is used to detect, quantify, or neutralize IL 4 in research or therapeutic settings, assisting in the study or modulation of immune responses in conditions such as allergies, asthma, and autoimmune disorders.
The main types of interleukin (IL) 4 antibody are monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are highly specific immunoglobulins derived from a single B cell clone that recognize a single epitope on interleukin (IL) 4 or its receptor. They are produced through hybridoma or recombinant expression systems and engineered for isotype, affinity, and effector function to ensure consistent performance in research and clinical applications. Their uses include enzyme-linked immunosorbent assay, immunohistochemistry frozen, immunohistochemistry paraffin, western blot, and others, and they are employed by end users such as pharmaceutical companies, biotechnology companies, academic and research institutions, and contract research organizations (CROs).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The interleukin (IL)-4 antibody market research report is one of a series of new reports from The Business Research Company that provides interleukin (IL)-4 antibody market statistics, including interleukin (IL)-4 antibody industry global market size, regional shares, competitors with a interleukin (IL)-4 antibody market share, detailed interleukin (IL)-4 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin (IL)-4 antibody industry. This interleukin (IL)-4 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The interleukin (IL)-4 antibody market size has grown strongly in recent years. It will grow from $2.13 billion in 2024 to $2.32 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of allergic and inflammatory diseases, rising adoption of monoclonal antibody therapies, growing awareness of immunotherapy treatments, increasing healthcare expenditure, and rising focus on personalized medicine.
The interleukin (IL)-4 antibody market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising incidence of chronic respiratory disorders, increasing demand for targeted biologic therapies, expanding clinical trials for autoimmune diseases, growing investment in biosimilar development, and increasing collaborations between pharma and biotech companies. Major trends in the forecast period include advancements in antibody engineering technologies, research and development in cytokine modulation, innovations in recombinant antibody production, development of next generation biologics, and integration of artificial intelligence based drug discovery platforms.
The increasing prevalence of allergic diseases is expected to drive the growth of the interleukin (IL) 4 antibody market going forward. Allergic diseases are immune system disorders in which the body reacts excessively to harmless substances such as pollen, dust, or food, resulting in symptoms such as inflammation, itching, and difficulty in breathing. The rising prevalence of allergic diseases is attributed to urbanization and environmental changes that increase exposure to pollutants and allergens that trigger immune overreactions. Interleukin (IL) 4 antibody assists in managing allergic diseases by specifically targeting IL 4 pathways, making it effective in reducing immune system overreactions. It helps relieve symptoms such as inflammation, itching, and difficulty in breathing, improving patient comfort and quality of life. For instance, in February 2025, according to the National Asthma Council Australia (NAC), an Australia-based not-for-profit organization, Australia recorded a total of 474 asthma related deaths, reflecting a slight year on year increase of 0.2 percent from 473 deaths in 2022, with females accounting for 68.6 percent and males comprising 31.4 percent. Therefore, the increasing prevalence of allergic diseases is driving the growth of the interleukin (IL) 4 antibody market.
Major companies operating in the interleukin (IL) 4 antibody market are concentrating on developing innovative products such as next generation bispecific antibodies to address tumor resistance and enhance anti cancer effectiveness. Next generation bispecific antibodies refer to engineered antibodies designed to bind two different antigens or epitopes at the same time, enhancing therapeutic performance by modulating multiple pathways simultaneously, improving specificity, and potentially reducing adverse effects compared to traditional single target antibodies. For instance, in February 2025, Akeso Inc., a China based biopharmaceutical company, received Investigational New Drug (IND) acceptance from the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody. AK139 integrates dual targeting of interleukin 4 receptor alpha and the ST2 receptor to block the interleukin 4 interleukin 13 and interleukin 33 pathways simultaneously, offering mechanistic synergy beyond single target antibodies. This approach aims to reduce inflammatory cytokine release and tissue infiltration more effectively, potentially providing stronger and more sustained control of type 2 and related inflammation in respiratory and dermatological conditions.
In June 2025, Bio T Hera Solutions Ltd., a China-based biopharmaceutical company, partnered with SteinCares S A to commercialize a proposed biosimilar of dupilumab for the treatment of chronic inflammatory diseases across Latin America for an undisclosed amount. With this partnership, Bio T Hera Solutions aims to contribute its expertise in biologics development and supply, while SteinCares will oversee the registration and commercialization processes across the region. SteinCares S A is a US based specialty healthcare company focused on IL 4 antibody therapies and research products.
Major companies operating in the interleukin (il)-4 antibody market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., GeneTex Inc., Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, Cell Signaling Technology Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Santa Cruz Biotechnology Inc., Atlas Antibodies AB, Creative Biolabs Inc., Abnova (Taiwan) Corporation, Wuhan Fine Biotech Co. Ltd., United States Biological LLC, NSJ Bioreagents, Boster Biological Technology Co. Ltd.
North America was the largest region in the interleukin (IL)-4 antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interleukin (IL)-4 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the interleukin (IL)-4 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The interleukin (IL)-4 antibody market also includes sales of recombinant interleukin (IL)-4 neutralizing antibodies, bispecific interleukin (IL)-4 antibodies, biosimilar interleukin (IL)-4 antibodies, antibody conjugates, assay kits, and related immunoassay reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the antibodies, whether to other entities (including downstream manufacturers, wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Interleukin (IL)-4 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on interleukin (il)-4 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for interleukin (il)-4 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interleukin (il)-4 antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Monoclonal Antibodies; Polyclonal Antibodies
2) By Application: Enzyme Linked Immunosorbent Assay; Immunohistochemistry Frozen; Immunohistochemistry Paraffin; Western Blot; Other Applications
3) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs)
Subsegments:
1) By Monoclonal Antibodies: Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Murine Monoclonal Antibodies
3. Interleukin (IL)-4 Antibody Market Trends And Strategies
4. Interleukin (IL)-4 Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Interleukin (IL)-4 Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Interleukin (IL)-4 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Interleukin (IL)-4 Antibody Market Growth Rate Analysis
5.4. Global Interleukin (IL)-4 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Interleukin (IL)-4 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Interleukin (IL)-4 Antibody Total Addressable Market (TAM)
6.1. Global Interleukin (IL)-4 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
6.2. Global Interleukin (IL)-4 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Linked Immunosorbent Assay
Immunohistochemistry Frozen
Immunohistochemistry Paraffin
Western Blot
Other Applications
6.3. Global Interleukin (IL)-4 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Biotechnology Companies
Academic And Research Institutions
Contract Research Organizations (CROs)
6.4. Global Interleukin (IL)-4 Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Fully Human Monoclonal Antibodies
Murine Monoclonal Antibodies
6.5. Global Interleukin (IL)-4 Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rabbit Polyclonal Antibodies
Goat Polyclonal Antibodies
Sheep Polyclonal Antibodies
Mouse Polyclonal Antibodies
Donkey Polyclonal Antibodies
7. Interleukin (IL)-4 Antibody Market Regional And Country Analysis
7.1. Global Interleukin (IL)-4 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Interleukin (IL)-4 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
